Citadel Advisors
IMUC

Citadel Advisors’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Citadel Advisors’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-33
Closed -$1K – 8863
2014
Q2 		$1K Sell
33
-890
-96% -$42.9K ﹤0.01% 7916
2014
Q1 		$45K Sell
923
-250
-21% -$12.2K ﹤0.01% 6855
2013
Q4 		$43K Buy
1,173
+640
+120% +$60.6K ﹤0.01% 6136
2013
Q3 		$55K Buy
+533
New +$58.5K ﹤0.01% 5748

Other funds holding IMUC

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Citadel Advisors's IMUC Position: Q4 2018 in Review

Citadel Advisors sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 69,746 shares — an estimated $15K sold.

Citadel Advisors first reported a position in IMUC in Q3 2013 and held it in 12 quarters. The position peaked at $99K in Q1 2018. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

  • Citadel Advisors reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
  • Citadel Advisors sold 69,746 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018, an estimated $15K.
  • Citadel Advisors first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2013 and held it in 12 quarters.
  • Citadel Advisors's ImmunoCellular Therapeutics, Ltd. position peaked at $99K in Q1 2018.
  • 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.